143 related articles for article (PubMed ID: 8031320)
1. Inversely-correlated inhibition of human 5-lipoxygenase activity by BAY X1005 and other quinoline derivatives in intact cells and a cell-free system--implications for the function of 5-lipoxygenase activating protein.
Hatzelmann A; Goossens J; Fruchtmann R; Mohrs KH; Raddatz S; Müller-Peddinghaus R
Biochem Pharmacol; 1994 Jun; 47(12):2259-68. PubMed ID: 8031320
[TBL] [Abstract][Full Text] [Related]
2. Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds.
Hatzelmann A; Fruchtmann R; Mohrs KH; Raddatz S; Müller-Peddinghaus R
Biochem Pharmacol; 1993 Jan; 45(1):101-11. PubMed ID: 8381000
[TBL] [Abstract][Full Text] [Related]
3. Ca2+ ionophore A23187-stimulated secretion of azurophil granules in human polymorphonuclear leukocytes is largely mediated by endogenously formed leukotriene B4.
Hatzelmann A; Fruchtmann R; Mohrs KH; Raddatz S; Müller-Peddinghaus R
Biochem Pharmacol; 1994 Jul; 48(1):31-9. PubMed ID: 8043028
[TBL] [Abstract][Full Text] [Related]
4. Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: implications for biological regulation of 5-lipoxygenase.
Hatzelmann A; Fruchtmann R; Mohrs KH; Raddatz S; Matzke M; Pleiss U; Keldenich J; Müller-Peddinghaus R
Agents Actions; 1994 Nov; 43(1-2):64-8. PubMed ID: 7741044
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological modulation of human platelet leukotriene C4-synthase.
Sala A; Folco G; Henson PM; Murphy RC
Biochem Pharmacol; 1997 Mar; 53(6):905-8. PubMed ID: 9113110
[TBL] [Abstract][Full Text] [Related]
6. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis.
Fruchtmann R; Mohrs KH; Hatzelmann A; Raddatz S; Fugmann B; Junge B; Horstmann H; Müller-Peddinghaus R
Agents Actions; 1993 Mar; 38(3-4):188-95. PubMed ID: 8213345
[TBL] [Abstract][Full Text] [Related]
7. 5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors.
Evans JF; Lévillé C; Mancini JA; Prasit P; Thérien M; Zamboni R; Gauthier JY; Fortin R; Charleson P; MacIntyre DE
Mol Pharmacol; 1991 Jul; 40(1):22-7. PubMed ID: 1857337
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of antigen-induced contraction of guinea-pig airways by a leukotriene synthesis inhibitor, BAY x1005.
Gardiner PJ; Cuthbert NJ; Francis HP; Fitzgerald MF; Thompson AM; Carpenter TG; Patel UP; Newton BB; Mohrs K; Müller-Peddinghaus R
Eur J Pharmacol; 1994 Jun; 258(1-2):95-102. PubMed ID: 7925604
[TBL] [Abstract][Full Text] [Related]
9. 4-acylaminophenol derivatives as novel lipoxygenase inhibitors: synthesis and inhibitory effect on 5-lipoxygenase and leukotriene B4 production.
Kikuchi M; Hashimura Y; Tsuzurahara K; Nagasawa M; Inoue H; Taniguchi T; Uchida T
Biol Pharm Bull; 1994 Aug; 17(8):1038-46. PubMed ID: 7820104
[TBL] [Abstract][Full Text] [Related]
10. The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products.
Fischer L; Hornig M; Pergola C; Meindl N; Franke L; Tanrikulu Y; Dodt G; Schneider G; Steinhilber D; Werz O
Br J Pharmacol; 2007 Oct; 152(4):471-80. PubMed ID: 17704828
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition.
Charleson S; Prasit P; Léger S; Gillard JW; Vickers PJ; Mancini JA; Charleson P; Guay J; Ford-Hutchinson AW; Evans JF
Mol Pharmacol; 1992 May; 41(5):873-9. PubMed ID: 1588922
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor.
Brideau C; Chan C; Charleson S; Denis D; Evans JF; Ford-Hutchinson AW; Fortin R; Gillard JW; Guay J; Guévremont D
Can J Physiol Pharmacol; 1992 Jun; 70(6):799-807. PubMed ID: 1330258
[TBL] [Abstract][Full Text] [Related]
13. Intravenous anesthetic propofol binds to 5-lipoxygenase and attenuates leukotriene B
Okuno T; Koutsogiannaki S; Ohba M; Chamberlain M; Bu W; Lin FY; Eckenhoff RG; Yokomizo T; Yuki K
FASEB J; 2017 Apr; 31(4):1584-1594. PubMed ID: 28069825
[TBL] [Abstract][Full Text] [Related]
14. Acetyl-11-keto-beta-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity.
Sailer ER; Subramanian LR; Rall B; Hoernlein RF; Ammon HP; Safayhi H
Br J Pharmacol; 1996 Feb; 117(4):615-8. PubMed ID: 8646405
[TBL] [Abstract][Full Text] [Related]
15. (R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl] acetic acid (BAY x1005), a potent leukotriene synthesis inhibitor: effects on anti-IgE challenge in human airways.
Gorenne I; Labat C; Gascard JP; Norel X; Müller-Peddinghaus R; Mohrs KH; Taylor WA; Gardiner PJ; Brink C
J Pharmacol Exp Ther; 1994 Feb; 268(2):868-72. PubMed ID: 8114000
[TBL] [Abstract][Full Text] [Related]
16. BAY X1005, a new selective inhibitor of leukotriene synthesis: pharmacology and pharmacokinetics.
Müller-Peddinghaus R; Fruchtmann R; Ahr HJ; Beckermann B; Bühner K; Fugmann B; Junge B; Matzke M; Kohlsdorfer C; Raddatz S
J Lipid Mediat; 1993; 6(1-3):245-8. PubMed ID: 8395246
[TBL] [Abstract][Full Text] [Related]
17. Molecular pharmacological profile of a novel thiazolinone-based direct and selective 5-lipoxygenase inhibitor.
Hofmann B; Rödl CB; Kahnt AS; Maier TJ; Michel AA; Hoffmann M; Rau O; Awwad K; Pellowska M; Wurglics M; Wacker M; Zivković A; Fleming I; Schubert-Zsilavecz M; Stark H; Schneider G; Steinhilber D
Br J Pharmacol; 2012 Apr; 165(7):2304-13. PubMed ID: 21955369
[TBL] [Abstract][Full Text] [Related]
18. Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models.
Carty TJ; Sweeney FJ; Griffiths RJ; Eskra JD; Ernest MJ; Pillar JS; Cheng JD; Loose LD; Joseph PA; Pazoles PP; Moore PF; Nagahisa A; Murase S; Kadin SB
Inflamm Res; 1997 May; 46(5):168-79. PubMed ID: 9197987
[TBL] [Abstract][Full Text] [Related]
19. [Pyrrolo(2,3-c)quinolines and pyrrolo(3,4-d)quinolines--synthesis and investigation of lipoxygenase inhibition].
Görlitzer K; Fabian J; Frohberg P; Drutkowski G
Pharmazie; 2002 Apr; 57(4):243-9. PubMed ID: 11998442
[TBL] [Abstract][Full Text] [Related]
20. Dapsone inhibits the generation of 5-lipoxygenase products in human polymorphonuclear leukocytes.
Wozel G; Lehmann B
Skin Pharmacol; 1995; 8(4):196-202. PubMed ID: 7488396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
